近期，创新药IPO如火如荼！ 格隆汇获悉，珠海泰诺麦博制药股份有限公司（简称"泰诺麦博"）于7月31日向上交所递交了招股书，拟采用第五套标 准寻求科创板上市，由华泰联合证券担任保荐人。 这也是科创板第五套标准重启以来，首家受理的公司。 值得注意的是，就在昨天，来自广州的创新药企业必贝特在过会2年多之后，终于成功拿到了IPO注册路条。 而此前的7月，禾元生物和北芯生命先后过会，均是采用的科创板第五套标准。 这一系列事件，被业内解读为"又一个属于创新药行业的IPO窗口期正式开始"。 01 创始人是美国国籍，高瓴、康哲药业参投 泰诺麦博成立于2015年12月，由HUA XIN LIAO和郑伟宏联合创办，公司2023年6月完成股改，总部位于珠海市金湾 区。 目前，公司无控股股东，HUA XIN LIAO和郑伟宏为共同实际控制人，二人合计控制泰诺麦博33.1%的股权。 1953年出生的HUA XIN LIAO是美国国籍，在公司任董事长。他毕业于美国北卡罗莱纳大学教堂山分校生物化学专 业，博士学位。他曾任美国杜克大学助理教授、副教授、教授；回国后曾任暨南大学特聘教授、教授。 郑伟宏出生于1973年10月，中国国籍，毕业于 ...

Core Viewpoint - The recent surge in IPOs for innovative drug companies indicates the opening of a new window for the innovative drug industry, with several companies, including Zhuhai Tainomai Bo Pharmaceutical Co., Ltd., seeking to go public on the STAR Market [1][21]. Company Overview - Zhuhai Tainomai Bo Pharmaceutical Co., Ltd. was founded in December 2015 by HUA XIN LIAO and Zheng Weihong, with its headquarters located in Jinwan District, Zhuhai City [3][4]. - The company currently has no controlling shareholder, with HUA XIN LIAO and Zheng Weihong jointly controlling 33.1% of the shares [4]. Investment and Valuation - Tainomai Bo has undergone multiple rounds of financing, with major institutional investors including Hillhouse Capital and Kangzhe Pharmaceutical. The post-investment valuation was approximately 5.273 billion yuan in March 2025 [5]. - The company aims to meet the listing standards of the STAR Market, with an expected market value of no less than 4 billion yuan and at least one core product approved for Phase II clinical trials [5]. Product Pipeline - The company focuses on blood product alternatives, with its core product, Staitouta Monoclonal Antibody Injection, already on the market. It is the world's first recombinant anti-tetanus toxin monoclonal antibody drug [6][9]. - Tainomai Bo is developing eight antibody drugs and candidates, including TNM001, which is in Phase III clinical trials for respiratory syncytial virus (RSV) prevention [7][15]. Financial Performance - The company has reported significant losses over the past three years, totaling over 1.567 billion yuan, with plans to raise 1.5 billion yuan through the IPO to fund new drug development and expand its antibody production base [17][19]. - Revenue from the core product Staitouta Monoclonal Antibody Injection began in March 2025, following its approval in February 2025, with initial sales of 169,300 yuan [18]. Market Competition - The Staitouta Monoclonal Antibody Injection faces competition from traditional blood products and other monoclonal antibody products currently in development, which may impact its market penetration [11][12][21]. - The company must effectively promote its innovative product to gain recognition among healthcare professionals and patients to overcome the challenges posed by established competitors [11][21].